Agendia Study Demonstrates MammaPrint® and BluePrint® Capture Full Spectrum of Early Breast Cancer Biology, Providing Opportunity for Highly Individualized Treatment
New analysis in peer-reviewed journal Genes, Chromosomes and Cancer Read More
New analysis in peer-reviewed journal Genes, Chromosomes and Cancer Read More
Weitere Kooperation mit zertifiziertem Speziallabor Mehr Informationen für individuelle Therapien Read More
AI solution will expand Agendia’s testing platform in the Brazilian Read More
Multi-year partnership to advance the use of next-generation sequencing for Read More
IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – January 6, 2022 Read More
Additional research from the real-world FLEX Registry focuses on age Read More
Data signal importance of serial genomic testing in order to Read More
ER+ tumors reclassified by BluePrint as Basal-type occur at a Read More
PUBLICATION: ASCO 2021 Authors Joyce O’Shaughnessy1, Virginia G. Kaklamani2, Read More
PUBLICATION: ASCO 2021 Authors Cathy Graham1, Douglas K. Marks2, Read More